
## Renée Turzanski Fortner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3078411/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3). International Journal of Epidemiology, 2022, 51, e73-e86.	0.9	5
2	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	1.1	2
3	Prediagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma. International Journal of Cancer, 2022, 150, 1255-1268.	2.3	18
4	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
5	Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer. British Journal of Cancer, 2022, 126, 1301-1309.	2.9	22
6	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8<sup>+</sup> TIL</scp> infiltration, and provides no independent prognostic value in endometriosisâ€associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	2.1	15
7	Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study. American Journal of Obstetrics and Gynecology, 2022, 226, 821.e1-821.e26.	0.7	14
8	Circulating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohort. BMC Medicine, 2022, 20, 118.	2.3	7
9	Weight change in middle adulthood and risk of cancer in the European Prospective Investigation into Cancer and Nutrition ( <scp>EPIC</scp> ) cohort. International Journal of Cancer, 2021, 148, 1637-1651.	2.3	23
10	Adiposity and Endometrial Cancer Risk in Postmenopausal Women: A Sequential Causal Mediation Analysis. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 104-113.	1.1	17
11	Genital powder use and risk of uterine cancer: A pooled analysis of prospective studies. International Journal of Cancer, 2021, 148, 2692-2701.	2.3	4
12	Dietary intake of trans fatty acids and breast cancer risk in 9 European countries. BMC Medicine, 2021, 19, 81.	2.3	24
13	Causal Effects of Lifetime Smoking on Breast and Colorectal Cancer Risk: Mendelian Randomization Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 953-964.	1.1	15
14	Metabolic signatures of greater body size and their associations with risk of colorectal and endometrial cancers in the European Prospective Investigation into Cancer and Nutrition. BMC Medicine, 2021, 19, 101.	2.3	24
15	Dietary Methyl-Group Donor Intake and Breast Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Nutrients, 2021, 13, 1843.	1.7	4
16	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. Carcinogenesis, 2021, 42, 785-793.	1.3	6
17	<i>Chlamydia trachomatis</i> , Pelvic Inflammatory Disease, and Epithelial Ovarian Cancer. Journal of Infectious Diseases, 2021, 224, S121-S127.	1.9	13
18	Endogenous Circulating Sex Hormone Concentrations and Colon Cancer Risk in Postmenopausal Women: A Prospective Study and Meta-Analysis. JNCI Cancer Spectrum, 2021, 5, pkab084.	1.4	8

## Renée Turzanski Fortner

#	Article	IF	CITATIONS
19	Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947–1964: The Nurses' Health Study II, a prospective cohort study. European Journal of Epidemiology, 2021, 36, 827-839.	2.5	12
20	Risk Prediction for Renal Cell Carcinoma: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) Prospective Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 507-512.	1.1	6
21	Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology, 2021, , .	0.6	5
22	A nutrient-wide association study for risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition and the Netherlands Cohort Study. European Journal of Nutrition, 2020, 59, 2929-2937.	1.8	11
23	Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2020, 146, 3267-3280.	2.3	14
24	Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2010-2018.	1.1	6
25	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case–control studies. European Journal of Epidemiology, 2020, 35, 1025-1042.	2.5	2
26	Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: A Prospective Study in the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1654-1664.	1.1	3
27	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
28	Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncology, 2020, 6, e200421.	3.4	78
29	Dietary and Circulating Fatty Acids and Ovarian Cancer Risk in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1739-1749.	1.1	15
30	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	0.6	15
31	The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3). Cancer Research, 2020, 80, 1210-1218.	0.4	35
32	Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ: results from the EPIC-Heidelberg cohort. Breast Cancer Research, 2020, 22, 23.	2.2	20
33	Circulating Immune Cell Composition and Cancer Risk: A Prospective Study Using Epigenetic Cell Count Measures. Cancer Research, 2020, 80, 1885-1892.	0.4	13
34	Association between lifestyle, dietary, reproductive, and anthropometric factors and circulating 27-hydroxycholesterol in EPIC-Heidelberg. Cancer Causes and Control, 2020, 31, 181-192.	0.8	8
35	Theoretical potential for endometrial cancer prevention through primary risk factor modification: Estimates from the EPIC cohort. International Journal of Cancer, 2020, 147, 1325-1333.	2.3	6
36	Serologic markers of <i>Chlamydia trachomatis</i> and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the <scp>EPIC</scp> cohort. International Journal of Cancer, 2020, 147, 2042-2052.	2.3	26

#	Article	IF	CITATIONS
37	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.4	49
38	Circulating insulinâ€like growth factor I in relation to melanoma risk in the European prospective investigation into cancer and nutrition. International Journal of Cancer, 2019, 144, 957-966.	2.3	12
39	Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. Journal of the National Cancer Institute, 2019, 111, 137-145.	3.0	43
40	Circulating 27-Hydroxycholesterol and Breast Cancer Risk: Results From the EPIC-Heidelberg Cohort. Journal of the National Cancer Institute, 2019, 111, 365-371.	3.0	45
41	Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1746-1754.	1.1	8
42	High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium. Cancer Research, 2019, 79, 5442-5451.	0.4	36
43	Prospective analysis of circulating metabolites and breast cancer in EPIC. BMC Medicine, 2019, 17, 178.	2.3	79
44	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
45	Sex hormone binding globulin and risk of breast cancer: a Mendelian randomization study. International Journal of Epidemiology, 2019, 48, 807-816.	0.9	50
46	Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies. British Journal of Cancer, 2019, 120, 855-860.	2.9	23
47	Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies. Breast Cancer Research, 2019, 21, 40.	2.2	81
48	Predicting Circulating CA125 Levels among Healthy Premenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1076-1085.	1.1	9
49	Association of menopausal characteristics and risk of coronary heart disease: a pan-European case–cohort analysis. International Journal of Epidemiology, 2019, 48, 1275-1285.	0.9	47
50	Development and validation of circulating CA125 prediction models in postmenopausal women. Journal of Ovarian Research, 2019, 12, 116.	1.3	12
51	Biomarkers of Vascular Injury and Type 2 Diabetes: A Prospective Study, Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2019, 8, 2075.	1.0	6
52	Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and risk of in situ breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. BMC Medicine, 2019, 17, 221.	2.3	18
53	Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium. International Journal of Cancer, 2019, 145, 58-69.	2.3	28
54	Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition. American Journal of Epidemiology, 2019, 188, 274-281.	1.6	6

#	Article	IF	CITATIONS
55	Coffee and tea drinking in relation to the risk of differentiated thyroid carcinoma: results from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. European Journal of Nutrition, 2019, 58, 3303-3312.	1.8	9
56	A comprehensive gene–environment interaction analysis in Ovarian Cancer using genomeâ€wide significant common variants. International Journal of Cancer, 2019, 144, 2192-2205.	2.3	12
57	Tumorâ€associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. International Journal of Cancer, 2018, 143, 515-526.	2.3	18
58	Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 790-804.	1.1	6
59	Reproducibility of serum oxysterols and lanosterol among postmenopausal women: Results from EPIC-Heidelberg. Clinical Biochemistry, 2018, 52, 117-122.	0.8	19
60	Results from the European Prospective Investigation into Cancer and Nutrition Link Vitamin B6 Catabolism and Lung Cancer Risk. Cancer Research, 2018, 78, 302-308.	0.4	18
61	Antiâ€Müllerian hormone and risk of ovarian cancer in nine cohorts. International Journal of Cancer, 2018, 142, 262-270.	2.3	5
62	Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: The EPIC study. International Journal of Cancer, 2018, 142, 1332-1342.	2.3	42
63	Ovarian cancer early detection by circulating <scp>CA</scp> 125 in the context of antiâ€ <scp>CA</scp> 125 autoantibody levels: Results from the <scp>EPIC</scp> cohort. International Journal of Cancer, 2018, 142, 1355-1360.	2.3	24
64	Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts. Breast Cancer Research, 2018, 20, 147.	2.2	24
65	Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort. BMC Cancer, 2018, 18, 1010.	1.1	9
66	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
67	Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study. BMC Cancer, 2018, 18, 616.	1.1	47
68	Nonsteroidal antiâ€inflammatory drug use and breast cancer risk in a European prospective cohort study. International Journal of Cancer, 2018, 143, 1688-1695.	2.3	11
69	Dietary and lifestyle determinants of acrylamide and glycidamide hemoglobin adducts in non-smoking postmenopausal women from the EPIC cohort. European Journal of Nutrition, 2017, 56, 1157-1168.	1.8	17
70	Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium. Cancer Causes and Control, 2017, 28, 429-435.	0.8	3
71	Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort. Clinical Cancer Research, 2017, 23, 4181-4189.	3.2	26
72	Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort. BMC Medicine, 2017, 15, 26.	2.3	21

#	Article	IF	CITATIONS
73	Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort. Journal of Ovarian Research, 2017, 10, 20.	1.3	22
74	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
75	Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium. Cancer Research, 2017, 77, 3951-3960.	0.4	48
76	Endometrial cancer risk prediction including serum-based biomarkers: results from the EPIC cohort. International Journal of Cancer, 2017, 140, 1317-1323.	2.3	28
77	Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort. Cancer Prevention Research, 2017, 10, 525-534.	0.7	29
78	A Comparative Study on the WCRF International/University of Bristol Methodology for Systematic Reviews of Mechanisms Underpinning Exposure–Cancer Associations. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1583-1594.	1.1	6
79	Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection. Gynecologic Oncology, 2017, 147, 465-480.	0.6	54
80	Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort. Cancer Research, 2017, 77, 134-141.	0.4	7
81	Prediagnostic circulating concentrations of plasma insulinâ€like growth factorâ€ <scp>I</scp> and risk of lymphoma in the <scp>E</scp> uropean <scp>P</scp> rospective <scp>I</scp> nvestigation into <scp>C</scp> ancer and <scp>N</scp> utrition. International Journal of Cancer, 2017, 140, 1111-1118.	2.3	7
82	Early pregnancy sex steroids during primiparous pregnancies and maternal breast cancer: a nested case–control study in the Northern Sweden Maternity Cohort. Breast Cancer Research, 2017, 19, 82.	2.2	7
83	Selecting high-risk individuals for lung cancer screening; the use of risk prediction models vs. simplified eligibility criteria. Annals of Translational Medicine, 2017, 5, 406-406.	0.7	9
84	The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS ONE, 2016, 11, e0147029.	1.1	102
85	Obesity and Breast Cancer. Recent Results in Cancer Research, 2016, 208, 43-65.	1.8	41
86	A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. Clinical Cancer Research, 2016, 22, 4664-4675.	3.2	80
87	Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy and Childbirth, 2016, 16, 146.	0.9	152
88	Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II. Breast Cancer Research and Treatment, 2016, 158, 149-155.	1.1	2
89	A treelet transform analysis to relate nutrient patterns to the risk of hormonal receptor-defined breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutrition, 2016, 19, 242-254.	1.1	26
90	Acrylamide and Glycidamide Hemoglobin Adducts and Epithelial Ovarian Cancer: A Nested Case–Control Study in Nonsmoking Postmenopausal Women from the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 127-134.	1.1	27

#	Article	IF	CITATIONS
91	Vegetable and fruit consumption and the risk of hormone receptor–defined breast cancer in the EPIC cohort. American Journal of Clinical Nutrition, 2016, 103, 168-177.	2.2	48
92	Nutrient-wide association study of 57 foods/nutrients and epithelial ovarian cancer in the European Prospective Investigation into Cancer and Nutrition study and the Netherlands Cohort Study. American Journal of Clinical Nutrition, 2016, 103, 161-167.	2.2	29
93	Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2015, 136, 399-410.	2.3	36
94	Reproductive factors and risk of mortality in the European Prospective Investigation into Cancer and Nutrition; a cohort study. BMC Medicine, 2015, 13, 252.	2.3	53
95	Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study. Breast Cancer Research, 2015, 17, 49.	2.2	30
96	Early pregnancy <scp>IGFâ€I</scp> and placental <scp>GH</scp> and risk of epithelial ovarian cancer: A nested caseâ€control study. International Journal of Cancer, 2015, 137, 439-447.	2.3	11
97	Reproductive and hormoneâ€related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort. International Journal of Cancer, 2015, 137, 1196-1208.	2.3	53
98	Investigation of Dietary Factors and Endometrial Cancer Risk Using a Nutrient-wide Association Study Approach in the EPIC and Nurses' Health Study (NHS) and NHSII. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 466-471.	1.1	42
99	Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study. British Journal of Cancer, 2015, 113, 1622-1631.	2.9	29
100	Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 951-961.	1.1	51
101	Dietary Intake of Acrylamide and Epithelial Ovarian Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 291-297.	1.1	16
102	Early Pregnancy Sex Steroids and Maternal Breast Cancer: A Nested Case–Control Study. Cancer Research, 2014, 74, 6958-6967.	0.4	15
103	Dietary fat intake and risk of epithelial ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology, 2014, 38, 528-537.	0.8	16
104	Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II. Breast Cancer Research, 2013, 15, R19.	2.2	63